These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2127690)

  • 21. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
    Bruckner HW; Cohen CJ; Feuer E; Holland JF
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
    Coleman M; Pasmantier MW; Silver RT
    Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemotherapy of epithelial ovarian carcinoma].
    Bruntsch U; Gallmeier WM
    MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
    [No Abstract]   [Full Text] [Related]  

  • 24. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Neth J Med; 1979; 22(2):38-44. PubMed ID: 107464
    [No Abstract]   [Full Text] [Related]  

  • 26. The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
    Posada JG; Marantz AB; Yeung KY; Smith FP; Delgado G; Edwards BK; Schein PS
    Gynecol Oncol; 1985 Jan; 20(1):23-31. PubMed ID: 3917421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination chemotherapy and immune capacity in advanced ovarian carcinoma.
    ten Berge RJ; Schellekens PT; Hamerlynck JV; Bruning PF
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):91-8. PubMed ID: 6420161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of advanced ovarian cancer].
    de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
    Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
    Bertelsen K; Jakobsen A; Andersen JE; Ahrons S; Pedersen PH; Kiaer H; Arffmann E; Bichel P; Boestofte E; Strøyer I
    Gynecol Oncol; 1987 Oct; 28(2):161-9. PubMed ID: 3311924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
    Sipilä P; Kivinen S; Gröhn P; Vesala J; Heinonen E
    Gynecol Oncol; 1989 Jul; 34(1):27-9. PubMed ID: 2500386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
    Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
    J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
    Grosh WW; Jones HW; Burnett LS; Greco FA
    Gynecol Oncol; 1986 Nov; 25(3):334-9. PubMed ID: 3023205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.
    Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Reisman AZ; Gusberg SB; Holland JF
    Am J Obstet Gynecol; 1983 Mar; 145(6):653-8. PubMed ID: 6402934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Kooyman CD; van Houwelingen JC; Pinedo HM
    Cancer; 1984 Apr; 53(7):1467-72. PubMed ID: 6421472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
    Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
    Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
    Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
    Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
    Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.